Can Cymbalta cause hair loss? It is a question many people taking duloxetine ask, and the short answer is yes — though rarely. Hair loss (alopecia) is listed as an uncommon adverse reaction in the UK Summary of Product Characteristics for duloxetine (Cymbalta), affecting an estimated 1 in 1,000 to 1 in 100 patients. Understanding why this happens, how to assess whether duloxetine is truly the cause, and what your options are if it is affecting you can help you have a more informed conversation with your GP or prescribing clinician.

Does Cymbalta Cause Hair Loss?

Yes — alopecia is listed as an uncommon adverse reaction to duloxetine (Cymbalta) in the UK SmPC, estimated to affect 1 in 1,000 to 1 in 100 patients, though the precise mechanism is not fully understood.

Experiencing these side effects? Our pharmacists can help you navigate them →

Cymbalta is the brand name for duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) licensed in the UK for major depressive disorder, generalised anxiety disorder, and diabetic peripheral neuropathic pain. (Duloxetine is also available as Yentreve, a separate licensed product indicated for stress urinary incontinence in women — this is a distinct brand and indication from Cymbalta.)

Hair loss — medically termed alopecia — is listed as an uncommon adverse reaction in the UK Summary of Product Characteristics (SmPC) for duloxetine (Cymbalta), meaning it is estimated to affect between 1 in 1,000 and 1 in 100 patients. This classification is based on post-marketing surveillance data reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA).

Whilst alopecia is a recognised adverse reaction, the precise mechanism by which duloxetine may contribute to hair loss in some individuals is not fully understood, and establishing causation in any individual case can be difficult. Hair thinning has many potential causes — including underlying health conditions, nutritional deficiencies, and concurrent medications — and these must be considered alongside any possible drug effect.

If you are experiencing hair thinning whilst taking Cymbalta, speak to your GP or prescribing clinician before making any changes to your medication. Do not stop duloxetine suddenly, as abrupt discontinuation can cause withdrawal-like effects including dizziness, nausea, and sensory disturbances. If you suspect your hair loss may be related to duloxetine, you or your clinician can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Not sure if this is normal? Chat with one of our pharmacists →

How Common Is Hair Loss With Duloxetine?

Hair loss with duloxetine is classified as uncommon, affecting an estimated 1 in 1,000 to fewer than 1 in 100 patients according to the UK SmPC, though under-reporting means true frequency in clinical practice may differ.

According to the UK SmPC for duloxetine (Cymbalta), alopecia is classified as an uncommon adverse reaction, occurring in an estimated 1 in 1,000 to fewer than 1 in 100 patients. This places it outside the category of common side effects (affecting more than 1 in 100 people), such as nausea, headache, dry mouth, and fatigue, but it is a recognised and listed adverse reaction.

The MHRA's Yellow Card scheme, which collects reports of suspected adverse drug reactions in the UK, has received reports linking duloxetine to alopecia. It is important to understand that Yellow Card data reflect suspected associations rather than confirmed causation, and they cannot be used to calculate the true incidence of an adverse reaction. Under-reporting is common in spontaneous pharmacovigilance systems, so the actual frequency in clinical practice may differ from SmPC estimates.

Several published case reports and small observational studies have described patients experiencing diffuse hair thinning after starting duloxetine, with hair regrowth occurring after the drug was discontinued or switched. These reports are clinically informative but do not constitute robust epidemiological evidence. Key points to bear in mind include:

• Hair loss affects many people for reasons unrelated to medication, including thyroid disorders, iron deficiency anaemia, and telogen effluvium triggered by stress or illness.

• The timing of hair loss relative to starting duloxetine is an important clue, but coincidence is possible.

• Individual susceptibility may play a role, as genetic and hormonal factors influence how people respond to medications.

If hair loss is a concern, a thorough clinical assessment is essential before attributing it solely to duloxetine.

Why Some Antidepressants Affect Hair Growth

Antidepressants such as duloxetine may trigger telogen effluvium by altering serotonin and noradrenaline signalling in hair follicles, though the underlying mental health condition and physiological stress can independently cause the same effect.

To understand why antidepressants might occasionally contribute to hair loss, it helps to consider the biology of hair growth. Hair follicles cycle through three phases: anagen (active growth), catagen (transition), and telogen (resting/shedding). Disruption to this cycle — particularly a premature shift into the telogen phase — results in a condition called telogen effluvium, characterised by diffuse shedding across the scalp. Importantly, telogen effluvium typically becomes noticeable two to three months after the triggering event, which can make it harder to identify the cause.

Serotonin and norepinephrine (noradrenaline), the neurotransmitters targeted by duloxetine, are not only active in the brain but are also present in peripheral tissues, including the skin and hair follicles. There is emerging evidence that serotonin signalling plays a modulatory role in hair follicle cycling. By altering serotonin and noradrenaline availability, SNRIs and SSRIs (selective serotonin reuptake inhibitors) may theoretically influence follicular activity, though the precise mechanism in humans remains poorly understood.

Additionally, the physiological stress of starting a new medication — or the underlying mental health condition itself — can trigger telogen effluvium independently of the drug's pharmacological action. Depression and anxiety are associated with elevated cortisol levels, which are known to disrupt hair growth cycles. This makes it genuinely difficult to disentangle drug-related effects from disease-related effects.

Other antidepressants, including fluoxetine, sertraline, and venlafaxine, have also been associated with rare reports of hair loss, suggesting this may be a class-related phenomenon rather than specific to duloxetine. Nonetheless, the evidence base remains limited, and clinicians are advised to consider all possible causes before attributing alopecia to any single medication.

What to Do If You Notice Hair Thinning on Cymbalta

Speak to your GP before making any medication changes, as duloxetine must not be stopped suddenly due to its recognised discontinuation syndrome; your clinician will investigate other treatable causes such as thyroid dysfunction or iron deficiency.

If you notice increased hair shedding or thinning whilst taking duloxetine, the most important first step is to speak to your GP or prescribing clinician before making any changes to your medication. Do not stop taking Cymbalta suddenly, as duloxetine has a recognised discontinuation syndrome. Symptoms of abrupt withdrawal can include:

• Dizziness and balance disturbances

• Electric shock-like sensations (sometimes called 'brain zaps')

• Nausea and vomiting

• Irritability and mood changes

Your GP will carry out a clinical assessment to identify or exclude other common causes of hair loss. As clinically indicated, this may include blood tests such as:

• Thyroid function (TSH, free T4) — hypothyroidism is a frequent and treatable cause of hair thinning

• Full blood count and ferritin — iron deficiency is common, particularly in women of reproductive age

• Vitamin B12 and vitamin D levels — where deficiency is suspected based on history or examination

• Hormonal profile if relevant (for example, androgens in women with pattern hair loss)

Seek prompt medical attention if you notice any of the following, as these may indicate a cause requiring specialist assessment: rapidly spreading or patchy hair loss, scalp inflammation, redness, pustules or scarring, or hair loss accompanied by systemic symptoms such as unexplained weight change, fatigue, or skin changes.

If investigations are normal and the timeline strongly suggests a link to duloxetine, your clinician may consider adjusting the dose, switching to an alternative antidepressant, or referring you to a dermatologist for specialist assessment. NICE guidance on depression (NG222) supports shared decision-making in treatment choices, meaning your concerns about side effects should be taken seriously and factored into your care plan.

Keeping a symptom diary noting when hair loss began relative to medication changes can be a helpful tool to bring to your appointment. If you believe duloxetine may be causing your hair loss, you or your clinician can report this suspected adverse reaction to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Alternative Treatments If Hair Loss Is a Concern

If hair loss is thought to be related to duloxetine, alternatives such as SSRIs (e.g. sertraline) or mirtazapine may be considered, though no antidepressant is entirely free from the theoretical risk of alopecia.

If hair loss is significantly affecting your quality of life and is thought to be related to duloxetine, there are several alternative antidepressant and anxiolytic options that may be considered in discussion with your prescribing clinician. It is essential that any switch is managed carefully and gradually to avoid discontinuation effects and to ensure your mental health condition remains well controlled.

Alternative pharmacological options may include:

• SSRIs such as sertraline or escitalopram — these are first-line treatments recommended by NICE for depression (NG222) and generalised anxiety disorder (CG113), and have a broadly similar efficacy profile to duloxetine for many patients, though they too carry rare reports of alopecia

• Mirtazapine — a noradrenergic and specific serotonergic antidepressant (NaSSA) with a different mechanism of action, which may suit some patients, particularly those with sleep disturbance or poor appetite

• Bupropion — not licensed for depression in the UK (it is licensed here only for smoking cessation, as Zyban); any consideration of bupropion for depression would be off-label and should only occur under specialist guidance

• Psychological therapies — NICE recommends cognitive behavioural therapy (CBT) as an effective treatment for both depression and generalised anxiety disorder, either alone or in combination with medication

It is worth noting that no antidepressant is entirely free from the theoretical risk of hair loss, and switching medications does not guarantee resolution of the problem. In many reported cases, hair regrowth occurred spontaneously over several months even without changing treatment.

If hair loss persists regardless of medication changes, your GP may refer you to an NHS dermatologist to explore other underlying causes and treatment options. Topical minoxidil is licensed for androgenetic alopecia (pattern hair loss); its use for telogen effluvium is off-label and should only be considered under clinician guidance. Always ensure any decision to change or stop medication is made collaboratively with your healthcare team.

Frequently Asked Questions